Antios therapeutics and assembly biosciences announce clinical collaboration agreement to evaluate the combination of ati-2173 and vebicorvir in patients with chronic hepatitis b virus infection

Mendham, n.j., and south san francisco, calif, oct. 19, 2021 (globe newswire) -- antios therapeutics, inc. and assembly biosciences, inc. (nasdaq: asmb) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis b virus (hbv) infection. a single cohort in the ongoing antios phase 2a antt201 clinical trial will evaluate ati-2173, antios' investigational proprietary active site polymerase inhibitor nucleotide (aspin), vebicorvir (vbr), assembly bio's investigational lead core inhibitor candidate, and tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor.
ASMB Ratings Summary
ASMB Quant Ranking